Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events.
Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based …

Background & Aims We evaluated the efficacy and safety of upadacitinib, an oral selective
inhibitor of Janus kinase 1, as induction therapy for ulcerative colitis (UC). Methods We …

Background Quantitative bias analysis (QBA) measures study errors in terms of direction,
magnitude and uncertainty. This systematic review aimed to describe how QBA has been …

Introduction Inflammatory bowel disease (IBD) may be associated with several
extraintestinal comorbidities, including cardiovascular disease (CVD). Chronic inflammation …

Objectives To assess incidence rates (IRs) of VTE in patients with rheumatoid arthritis (RA)
on different DMARDs and DMARD switchers. Methods Adults with RA on a DMARD …

Background Crohn's disease (CD) is a chronic relapsing form of inflammatory bowel
disease, seriously threatening human beings health. However, the pathogenesis of CD is …

Patients with inflammatory bowel disease (IBD) have an increased risk of venous
thromboembolism (VTE). Alongside the traditional acquired and genetic risk factors for VTE …

Background Inflammatory bowel disease (IBD) has been associated with an increased risk
of thromboembolic vascular complications. Although studies from the National Inpatient …

In children with gastrointestinal disorders such as inflammatory bowel disease (IBD) and
intestinal failure (IF), the risk of venous thromboembolism (VTE) is increased. VTE may lead …

Purpose We evaluated the impact of collagenase clostridium histolyticum (CCH) on rates of
diagnosis, treatment, and corporal rupture in Peyronie's disease (PD). We examined the …